To assess the clinical utility of p‐tau181 testing, we examined whether results led to changes in (1) estimated diagnostic certainty; (2) prescription of medications typically used to treat AD, including acetylcholinesterase inhibitors (AchE), memantine, and/or newer amyloid‐targeted treatments; and (3) orders for additional confirmatory testing, including PET and CSF. This evidence concerns the gene ACHE and Alzheimer disease.